Jasinski Milosz, Wisniewski Przemyslaw, Bielinska Marta, Siekiera Jerzy, Kamecki Krzysztof, Salagierski Maciej
Urology Department, Collegium Medicum, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland.
Department of Urology, Institute of Oncology, Romanowskiej 2, 85-796 Bydgoszcz, Poland.
Cancers (Basel). 2024 Apr 17;16(8):1528. doi: 10.3390/cancers16081528.
Over the recent years, progress in imaging techniques has led to an increased detection of kidney tumours, including small renal masses. While surgery is still the standard of care, there is a growing interest in minimally invasive methods. Ultrasound (US)-guided percutaneous ablation is particularly attractive because it is a safe and relatively simple procedure. In this study, we investigated the results of US-guided percutaneous radiofrequency ablation (RFA) and partial nephrectomy (PN) in the treatment of cT1a renal cancers. Between August 2016 and February 2022, 271 patients with renal tumours underwent percutaneous RFA as initial treatment in our institution. In the same period, 396 patients with renal tumours underwent surgical tumour excision. For the purpose of this study, only patients with confirmed renal cancer with matched age and tumour characteristics (size, location) were selected for both groups. Thus, a group of 44 PN patients and 41 RFA patients were formed with the same qualification criteria for both groups. Parameters such as procedure length, blood loss, hospital stay, analgesics used, and pre- and post-procedural serum creatinine were compared between these groups. Patients followed up with contrast-enhanced CT. There was no significant difference in age, tumour size, tumour location, and creatinine levels between these groups. All procedures were generally well tolerated. During a median follow-up of 28 months, two cases of recurrence/residual disease were found in each group. The overall survival was 100% in both groups, and all patients were disease-free at the end of observation. Percutaneous RFA was associated with a significantly shorter procedure length and hospital stay, lower blood loss, and lower analgesics used than PN. In the selected group of renal cancer patients, US-guided percutaneous RFA was associated with a shorter hospital stay, less analgesics used, and a shorter procedure length than PN, without differences in the oncological results or kidney function.
近年来,成像技术的进步使得肾脏肿瘤(包括小肾肿块)的检出率有所提高。虽然手术仍是标准治疗方法,但人们对微创方法的兴趣日益浓厚。超声(US)引导下的经皮消融术特别有吸引力,因为它是一种安全且相对简单的手术。在本研究中,我们调查了US引导下经皮射频消融(RFA)和部分肾切除术(PN)治疗cT1a期肾癌的结果。2016年8月至2022年2月期间,271例肾肿瘤患者在我们机构接受了经皮RFA作为初始治疗。同期,396例肾肿瘤患者接受了手术肿瘤切除。为了本研究的目的,两组仅选择年龄和肿瘤特征(大小、位置)匹配的确诊肾癌患者。因此,形成了一组44例PN患者和41例RFA患者,两组具有相同的入选标准。比较了这些组之间的手术时间、失血量、住院时间、使用的镇痛药以及术前和术后血清肌酐等参数。患者接受了对比增强CT随访。这些组之间在年龄、肿瘤大小、肿瘤位置和肌酐水平方面无显著差异。所有手术一般耐受性良好。在中位随访28个月期间,每组均发现2例复发/残留疾病。两组的总生存率均为100%,所有患者在观察结束时均无疾病。与PN相比,经皮RFA的手术时间和住院时间明显更短,失血量更少,使用的镇痛药更少。在选定的肾癌患者组中,US引导下的经皮RFA与PN相比,住院时间更短,使用的镇痛药更少,手术时间更短,在肿瘤学结果或肾功能方面无差异。